Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by WCM Investment Management LLC

Key Points

• WCM Investment Management LLC increased its stake in Ultragenyx Pharmaceutical by 4.1%, owning over 210,000 shares valued at approximately $7.7 million.
• Institutional ownership in Ultragenyx Pharmaceutical is significantly high, with over 97% of the stock held by institutional investors and hedge funds.
• The company's recent quarterly earnings report showed a 13.2% increase in revenue year-over-year, although it still posted a loss per share of ($1.17).

WCM Investment Management LLC lifted its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 4.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 210,469 shares of the biopharmaceutical company's stock after buying an additional 8,256 shares during the period. WCM Investment Management LLC owned approximately 0.22% of Ultragenyx Pharmaceutical worth $7,686,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Parallel Advisors LLC raised its position in shares of Ultragenyx Pharmaceutical by 1,061.9% in the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 669 shares during the period. GAMMA Investing LLC increased its stake in shares of Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 323 shares in the last quarter. ANTIPODES PARTNERS Ltd purchased a new stake in Ultragenyx Pharmaceutical during the 1st quarter valued at about $57,000. Headlands Technologies LLC purchased a new stake in Ultragenyx Pharmaceutical during the 1st quarter valued at about $59,000. Finally, Covestor Ltd grew its stake in Ultragenyx Pharmaceutical by 86.8% during the 1st quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company's stock valued at $62,000 after acquiring an additional 795 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on RARE. Guggenheim reissued a "buy" rating and issued a $64.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Wedbush dropped their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research note on Monday, July 14th. Morgan Stanley dropped their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. Weiss Ratings reissued a "sell (e+)" rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, October 8th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $105.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, September 5th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $81.50.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,942 shares of the stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $31.51, for a total transaction of $250,252.42. Following the sale, the chief financial officer directly owned 98,227 shares in the company, valued at $3,095,132.77. This represents a 7.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $31.17, for a total transaction of $76,366.50. Following the sale, the executive vice president owned 73,271 shares in the company, valued at approximately $2,283,857.07. This trade represents a 3.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,456 shares of company stock worth $328,486. 5.50% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock opened at $33.97 on Friday. The firm's 50 day moving average price is $30.11 and its 200-day moving average price is $32.92. Ultragenyx Pharmaceutical Inc. has a one year low of $25.81 and a one year high of $57.97. The firm has a market cap of $3.27 billion, a P/E ratio of -6.14 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The firm had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. During the same period in the prior year, the business posted ($1.52) EPS. The business's revenue for the quarter was up 13.2% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, research analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.